The Latest Breaking News from Pfizer

The first COVID-19 shots for U.S. infants, toddlers and preschoolers moved a step closer Wednesday.

CHICAGO — Mary MacMillan is eager to get her 2-year-old son vaccinated against COVID-19, once vaccines are authorized for young kids. But she has a lot of questions about how to get the shots.

Children younger than 5 are the last group without access to the shots.

Adults had plenty of opportunities to get their COVID-19 vaccines. But it won't be as easy for those under age of 5.

U.S. government advisers met Wednesday to decide whether to endorse COVID-19 shots for the youngest children, moving the nation closer to vaccinations for all ages

Here's a roundup of top developments in the biotech space over the last 24 hours:

Pfizer Inc (NYSE:PFE) shared additional data from the Phase 2/3 EPIC-SR study of Paxlovid (nirmatrelvir and ritonavir tablets) in patients at standard risk for developing severe COVID-19.  In previously reported interim analyses, the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met. Non-significant 70% relative…

It's no secret that during the COVID-19 pandemic, the global life sciences industry shined. It ramped up development of everything from diagnostic tests to new vaccines — including two based on previously unproven messenger RNA technology —all within months instead of years.

Amid lower demand, Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) agreed to delay supplies of their Covid-19 shot to the European Union. Doses to be shipped from June to August would be sent in September and Q4. Reuters reports that the bloc is putting heat on Pfizer to restrict supplies further. The move comes two weeks after…